Hormonal specificity of modulation of N-methyl-D-aspartate (NMDA) receptors was investigated by comparing the effects of estradiol with tamoxifen or
It has been shown that the female sex steroid estradiol exerts profound effects on neuronal differentiation during development (Toran-Allerand et al. 1983 ) and recently, accumulating evidence support also a modulatory role of estrogens in the normal maintenance of brain function during aging (Simpkins et al. 1994) . Beneficial effects of estradiol in mood disorders (i.e., depression, pre-menstrual syndrome, post-natal depression), as well as mental diseases, such as schizophrenia and Gille de la Tourette's syndrome, have been reported (Di Paolo 1994; Fink et al. 1998 ). Moreover, a beneficial role of estradiol in neurodegenerative dis-eases, such as Alzheimer has been recently suggested (Tang et al. 1996; Henderson 1997; Inestrosa et al. 1998) . However, the mechanisms by which these effects of estrogens are yet to be fully characterized.
N-methyl-D-aspartate (NMDA) receptors, a subtype of ionotropic glutamate receptor, have been implicated, as mediators, in some effects of estradiol on morphological plasticity and related physiological and cognitive processes in the brain (Moriyoshi et al. 1991) . However, only few studies have directly investigated the role of estradiol in regulating NMDA receptors in rat and, in addition, these studies have focused on the effects of estradiol on hippocampal NMDA receptors (Woolley and McEwen 1992; Gazzaley et al. 1996; Woolley et al. 1997) . We have recently investigated the effects of estradiol on the NMDA receptors agonist sites in brain regions implicated in mental disorders, such as frontal cortex, striatum, and nucleus accumbens (Cyr et al. 2000a) . Our experiments showed that ovariectomy, as well as estradiol have regional specific effects since, for example, ovariectomy decreases NMDA receptor specific binding in hippocampal CA1 and dentate gyrus regions, whereas it has no effect in frontal cortex. In contrast, estradiol increases NMDA specific binding in the hippocampal CA1 and the dentate gyrus, but it decreases this binding in the frontal cortex (Cyr et al. 2000a ).
The present study sought to determine whether changes observed previously at the protein level after hormonal withdrawal due to ovariectomy or after estradiol treatment reflect changes at the level of gene transcription, as well as to determine which subunits of the NMDA receptor may be implicated in this hormonal modulation. Therefore, we have investigated by autoradiography the levels of NMDA receptors agonist sites using L-[ ]Ro 25-6981 two weeks after ovariectomy and chronic administration of estradiol in rats. We have also investigated by in situ hybridization, using specific oligonucleotides, the level of NMDA receptor subunits 1, 2A, and 2B mRNA. The regions of the brain chosen were those implicated in mental disorders such as cingulate, frontal, and parietal cortices, striatum, nucleus accumbens, and hippocampus.
Activity in the rat brain of estrogen receptor ligands which have shown tissue-specific estrogen agonist and/or antagonist effects in peripheral tissues has not been reported on NMDA receptor binding or expression. Tamoxifen, a mixed estrogen agonist-antagonist used in the prevention and treatment of breast cancer, is among the first generation of the selective estrogen receptor modulators considering that it acts as an estrogen antagonist in mammary tissue, whereas it mimics the effects of estrogen in other tissues (Sato et al. 1996) . Raloxifene, is among the second generation of selective estrogen receptor modulators and it acts as an estrogen antagonist in mammary and uterine tissues, whereas functions as an estrogen agonist in bone and cholesterol metabolism (Sato et al. 1996) . Raloxifene is used to treat osteoporosis (Levenson and Jordan 1999) . Hence, these two molecules act as estrogen agonist or antagonist depending on the peripheral tissue. Therefore, we sought brain effects on the NMDA receptors of selective estrogen receptor modulators separate from their uterine stimulation by analogy to their skeletal/ cardiovascular activity. We hypothesize that estrogen agonist or selective estrogen receptor modulators change neuronal activity by affecting various neurotransmitters in different brain areas, which can bring a novel equilibrium in the brain. The present study investigated the specificity of estradiol and estrogen-receptor directed drugs modulation of the NMDA receptors. This knowledge is potentially important for a better understanding of estrogen receptors and glutamate receptors interaction.
MATERIAL AND METHODS

Animals
Adults female Sprague-Dawley rats weighing approximately 250 Ϯ 10 g were purchased from Charles River Canada Inc., St-Constant, Quebec, Canada. They were housed two per cage and maintained at 22-23 Њ C for two weeks on a 12 h: 12 h light/dark cycle (lights on from 0700 to 1900). The rats received rat chow and water ad libitum. The protocols used in these experiments were all approved by the Laval University Animal Care Committee and all efforts were made to minimize animal suffering and to reduce the number of rats used.
Treatments
The experiment included age-matched adult rats randomly divided into six groups of nine animals each. The first group included non-ovariectomized intact control rats at random stages of the estrous cycle treated with vehicle and the remaining five groups consisted of two-weeks ovariectomized rats under anesthesia (1.5% halothane air mixture) treated with vehicle, 80 g/kg 17 ␤ -estradiol (SIGMA, St. Louis, MO), 1 mg/kg tamoxifen citrate (SIGMA), or 1 mg/kg raloxifene (gift of F. Labrie, Oncology and Molecular Endocrinology Research Center, Quebec, Canada). Raloxifene was synthesized in the laboratory of Dr F. Labrie; purity (99.10%) and identity were assessed by High Pressure Liquid Chromatography, An other group of ovariectomized rats received an experimental drug and the results are not presented. The drug doses were chosen for maximal occupancy of the estrogen receptors and the vehicle was chosen for maximal delivery (Martel et al. 1998) . Similar drug doses and vehicle were previously used to investigate the effects of estradiol, tamoxifen, and raloxifene on brain 5-HT 2A receptors (Cyr et al. 2000b) . Treatment began the day after ovariectomy once daily for 14 days; 0.5 ml/rat was injected subcutaneously as suspension, the vehicle consisting of 4% ethanol, 4% polyethylene glycol 600 (PEG-600), 1% gelatin, and 0.9% NaCl in water. The uterus of the rats were immediately removed after sacrifice, freed from connective and adipose tissue, and weighed.
Brain Sections Preparation
The animals were killed in the morning by decapitation and their brains were rapidly removed, quickly frozen in isopentane over dry ice, individually wrapped in aluminum foil, and kept at Ϫ 80 Њ C. Brains were immersed in Tissue-Tek (Miles Inc., Elkhart, USA) at Ϫ 20 Њ C, mounted on cryostat chucks, and cut into 20 m thick coronal sections. Adjacent coronal sections were from the prefrontal cortex to the striatal regions of the brain (Bregma 4.2 to 1.2 mm, n ϭ 80 sections) and from the hippocampal regions (Bregma Ϫ 3.0 to Ϫ 4.4 mm, n ϭ 40 sections) according to the atlas of Paxinos and Watson (1982) .
The effect of hormonal modulation was studied in these brain regions, which were chosen based upon their importance in mental diseases, such as schizophrenia and depression, their high density of NMDA receptor and their mRNA expression, and/or the presence of estrogen receptors. Sections were thawmounted on superfrost pre-cleaned slides (Trade Mark, Fisher, Nepean, Ontario, Canada) and were then vacuum-desiccated at 4 Њ C for 12 hours before storing them at Ϫ 80 Њ C.
L-[
H]glutamate Binding Autoradiography
Autoradiography of glutamate and NMDA receptor agonist sites using L-[ 3 H]glutamate was performed as previously described (Cyr et al. 2000a ). Slide-mounted brains sections were preincubated for 10 min at 30 Њ C in the incubation buffer: 50 mM Tris-Acetate, pH 7.2. Slides were dried briefly and then incubated with 100 nM L-[ To determine nonspecific binding, 0.2 mM of L-glutamic acid hydrochloride (Research Biochemical Inc. (RBI) Natik, USA) was added to the incubation buffer; to determine the specific binding of NMDA receptors, 100 M of NMDA acid (RBI) was added to the incubation buffer. Therefore, the specific binding of NMDA receptors was defined as the amount of L-[ H with calibrated standards (Microscale, Amersham) and exposed for 14 days. Autoradiograms were analyzed using the software package NIH Image 1.68 on a Power Macintosh 7100 assisted videodensitometry (Sony camera XC-77), which provide values of receptors densities expressed in fmol/mg of tissue.
Optical density measurements were performed on the total area of the cingulate, frontal, and parietal cortices, the dorsal and ventral part of the striatum, the nucleus accumbens, and the olfactory tubercle (Bregma 1.60 mm) (Paxinos and Watson 1982) , as well as on the total area of hippocampal CA1 and CA2/3 subfields (including oriens, pyramidal cell, and stratum radiatum layers) and molecular layer dentate gyrus (Bregma Ϫ 3.80 mm) (Paxinos and Watson 1982 Jaarsma et al. (1993) . Briefly, the slides were preincubated three times for 20 minutes in Tris-HCl buffer (50 mM, pH 8.0) at room temperature. Sections were then incubated with 20 nM of L-[ 3 H]CGP 39653 for 90 min at 4 Њ C in 50 mM TrisHCl buffer (pH 8.0) containing 30 units/ml of glutamate dehydrogenase (Boehringer Mannheim, Indianapolis, IN, USA), 1.1 mM nicotinamide-adenine dinucleotide (SIGMA), and 0.03% hydrazide (v/v; SIGMA). Sections were then rinsed three times for 20 sec at 4 Њ C in Tris-HCl buffer (50 mM, pH 8.0). Nonspecific binding was determined by adding 0.5 mM L-NMDA (SIGMA) to the incubation buffer and the binding was always less than 5%.
[ 3 H]Ro 25-6981 (26 Ci/mmol; gift from F. HoffmanLa Roche Ltd., Basel, Switzerland) is an ifenprodil derivative (Fischer et al. 1997; Mutel et al. 1998 ) but in contrast to [ (Paxinos and Watson 1982) of intact rats and ovariectomized rats (two weeks) that received vehicle once daily, s.c., or a replacement therapy for two weeks with 17␤-estradiol (80 g/kg), tamoxifen (1 mg/kg), or raloxifene (1mg/kg). Abbreviations: Acb, nucleus accumbens; Cg, cingulate cortex; CPu, caudate putamen (striatum); Fr, frontal cortex; Par, parietal cortex; Tu, olfactory tubercle. (Paxinos and Watson 1982) of intact rat. Abbreviations: GrDG, granular layer dentate gyrus; Mol, molecular layer dentate gyrus; Or, oriens layer; Py, pyramidal cell layer; Rad, stratum radiatum.
al. (1998) . Briefly, the slides were preincubated two times for 10 min in incubation buffer (Tris-HCl 50 mM, EDTA 10 mM, pH 7.6) at room temperature. Sections were then incubated with 5 nM of [ The total area of eight adjacent sections of the oriens layer and the stratum radiatum of hippocampal CA1 and CA2/3 subfields as well as the molecular layer dentate gyrus was measured (Bregma Ϫ4.00 mm) (Paxinos and Watson 1982) . Examples are shown in Figures 2, 5, and 10.
In Situ Hybridization of NMDA Receptors
In situ hybridization was performed using previously published sequences of oligonucleotides (Monyer et al. 1992) complementary to rat cRNA encoding subunits residues between transmembrane domains I and II, encoding amino acids 566-580 of the mature peptide NMDA receptors subunit 1 (5'-TTCCTCCTCCTCCTCACTGT-TCACCTTGAATCGGCCAAAGGGACT-3'), 567-579 of the NMDA receptors subunit 2A (5'-AGAAGGCCC-GTGGGGAGCTTTCCCTTTGGCTAAGTTTC-3'), and 557-572 of the NMDA receptors subunit 2B (5'-GGG-CCTCCTGGCTCTCTGCCATCGGCTAGGCACCTGTT-GTAACCC-3'); note that the sequence of the oligonucleotide against NMDA receptor subunit 1 mRNA detects a population of eight distinct isoforms of a number of alternative splice variants (Sugihara et al. 1992; Hollmann et al. 1993) . TM 20 cartridge (NEN). All the following steps were carried out in diethylpyrocarbonate (DEPC) treated water. Brain sections were dried in a desiccator at 4ЊC and fixed in 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.2) for 5 min. Slides were treated by triethanolamine (0.1 M, pH 8.0) containing 0.25% (v/v) acetic anhydride for 10 min and rinsed for 30 min in Tris-Glycine buffer (0.1 M -0.1 M). Slides were then alcohol dehydrated and placed in a desiccator 2-3 hrs prior to in situ hybridization histochemistry. Sections were hybridized overnight at 42ЊC in a solution containing 50% formamide, 0.6 M NaCl, 0.06 M sodium citrate (4 ϫ SSC), 10% dextran sulfate, and 15,000 cpm/l of probe.
Following incubation, the brain sections were washed with 50% formamide in 2 ϫ SSC at room temperature for 1 hour, in 1 ϫ SSC at room temperature for 1 hour, in 0.5 ϫ SSC at 37ЊC for 30 min, in 0.5 ϫ SSC at room temperature for 30 min, and in 0.5 ϫ SSC at 50ЊC for 30 min. The slides were then dehydrated by consecutive washes in increasing concentrations of ethanol and air dried.
To generate autoradiograms, sections were exposed to Kodak BioMax MR film for 5-10 days. Quantification of autoradiograms were carried out by densitometry image analysis using a transmission density scale (Stouffer Graphic Arts Equipment Co. Inc, South Bend, USA) and the software package NIH Image 1.68 on a Power Macintosh 7100 assisted videodensitometry (Sony camera XC-77, lens of 65 mm).
In order to evaluate NMDA receptor subunit 1 mRNA levels, the values for each group were the mean of six animals and the mean for each animal were obtained from measurements of the total area of eight adjacent sections of the cingulate, frontal, parietal, and piriform cortices, and striatum (Bregma 1.60 mm) (Paxinos and Watson 1982) . The measurements of the total area of eight adjacent sections of the pyramidal cell layer of the hippocampal CA1 and CA2/3 regions and the molecular layer dentate gyrus (Bregma Ϫ4.20 mm) (Paxinos and Watson 1982) were performed to evaluate NMDA receptor subunits 1, 2A, and 2B mRNA levels. In situ hybridization to evaluate NMDA receptors subunits 2A and 2B mRNA levels in cortical and striatal regions of the brain was not performed because of the lower level of expression found in these regions (Moriyoshi et al. 1991 , Monyer et al. 1992 . Examples are shown in Figure 2 .
Statistical Analysis
Experimental data for each brain area was compared by means of one way analysis of variance (ANOVA) using the software Statviews 4.51 for Macintosh Computer followed by post-hoc pairwise comparisons with a Fisher's probability of least significant difference test H]Glutamate (0.2 mM) specific binding to NMDA receptors in cingulate, as well as frontal and parietal cortices of intact rats and two-weeks ovariectomized rats that received vehicle once daily, s.c., or a two-week replacement therapy with 17␤-estradiol (80 g/kg), tamoxifen (1 mg/kg), or raloxifene (1 mg/kg). Results are expressed in fmol/mg of tissue Ϯ S.E.M. from six rats. For the cortical region, cingulate: F 5,29 ϭ 3.49, p ϭ .01 † † estradiol-treated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ 179.8, Critical difference ϭ 128.4, p ϭ .007); tamoxifen-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ 192.9, Critical difference ϭ 134.6, p ϭ .006); and raloxifene-treated ovariectomized compared to vehicletreated ovariectomized rats (Mean difference ϭ 190.7, Critical difference ϭ 128.4, p ϭ .005). For the cortical region, frontal: F 5,29 ϭ 1.88, p ϭ .12; and parietal F 5,27 ϭ 0.70, p ϭ .63.
(PLSD). A p Ͻ .05 was required for the results to be considered statistically significant. Statistical comparisons of log of uterine weights were used.
RESULTS
Uterine Stimulation
There was an overall statistically significant difference in uterine weights among the experimental groups (F 5,55 ϭ 64.732, p Ͻ .0001). The uterine weight of ovariectomized rats (205 Ϯ 11 mg), decreased by 62% (mean difference ϭ 0.415, critical difference ϭ 0.063, p Ͻ .0001) compared to the uterine weight of 540 Ϯ 47 mg of intact non-ovariectomized rats. Estradiol treatment stimulated uterine weights of ovariectomized rats up to 461 Ϯ 19 mg (compared to vehicle-treated ovariectomized rats; mean difference ϭ Ϫ0.355, critical difference ϭ 0.063, p Ͻ .0001), whereas tamoxifen stimulated uterine weights of ovariectomized rats up to 265 Ϯ 11 mg (compared to vehicletreated ovariectomized rats; mean difference ϭ Ϫ0.116, critical difference ϭ 0.063, p ϭ .0005) and raloxifene stimulated uterine weights of ovariectomized rats up to 238 Ϯ 10 mg (compared to vehicle-treated ovariectomized rats; mean difference ϭ Ϫ0.068, critical difference ϭ 0.063, p ϭ .0328), which is significantly less than estradiol compared to raloxifene (mean difference ϭ Ϫ0.287, critical difference ϭ 0.064, p Ͻ .0001) and tamoxifen (mean difference ϭ Ϫ0.240, critical difference ϭ 0.064, p Ͻ .0001). and dendate gyrus regions, the effect of ovariectomy and hormonal treatment did not reach statistical significance (Figure 3) . Similarly, no effect of ovariectomy or treatments were observed in parietal cortex, striatum, nucleus accumbens, olfactory tubercle, and in the hippocampal CA2/3 regions (data not shown).
L-[
NMDA Receptors Specific Binding
Cortical Region. The two weeks ovariectomy was without significant effect on the NMDA receptor specific binding in all of the cortices assayed. Estradiol treatment in ovariectomized rats decreased this receptor binding of 26% in the cingulate cortex (p ϭ .007) and this effect faded when moving towards the frontal cortex (20%) and the parietal cortex (11%) (Figure 4) . In ovariectomized rats, tamoxifen as well as raloxifene treatments mimicked the effects of estradiol treatment and decreased significantly NMDA receptor specific binding in the cingulate cortex and left unchanged this receptor binding in the frontal and parietal cortices ( Figure 4 ). We focused our experiments to the cingulate cortex to determine the effect of hormonal modulation on the NMDA competitive antagonist site; the cingulate cortex is the cortex where greatest effects of ovariectomy and treatments were observed (Figure 4) . Examples of total and non-specific binding of L-[ Striatal Region. A similar density was measured in the dorsal part (315 Ϯ 33 fmol/mg of tissue) of the striatum compared to the ventral part (354 Ϯ 39 fmol/mg of tissue). Ovariectomy and hormonal treatments gave similar results in the dorsal and ventral striatum. Therefore, the results of the total striatum are presented. Ovariectomy in rats left NMDA binding unchanged in the striatum and nucleus accumbens (Figures 1 and 7) . Estradiol, tamoxifen, and raloxifene treatments decreased NMDA receptor binding similarly in the striatum and nucleus accumbens of ovariectomized rats (Figure 7 ). Ovariectomy and treatments were without effects on the NMDA receptor binding density in olfactory tubercle of ovariectomized rats (Figure 7) . Hippocampal Region. In contrast to the other brain regions assayed, ovariectomy decreased NMDA receptor specific binding density by 35% in the CA1 region and by 29% in the dentate gyrus of the hippocampus (p ϭ .01 and .02, respectively) (Figure 8 ). Estradiol, tamoxifen, and raloxifene treatments prevented the ovariectomy induced decrease of NMDA receptor specific binding observed in these regions (Figure 8 ). No significant effects of ovariectomy or treatments on NMDA receptor specific binding were observed in hippocampal CA2/3 regions (Figure 8) .
The hippocampal L-[ 3 H]CGP 39653 specific binding was not affected by ovariectomy and treatments ( Figure  9 ). In contrast, [ 3 H]Ro 25-6981 specific binding decreased by 16% after ovariectomy in the oriens (p ϭ .004) and by 17% in the stratum radiatum layers of hippocampal CA1 region (p ϭ .01); estradiol, tamoxifen, and raloxifene treatments prevented the ovariectomy induced decrease of this binding (Figures 9 and 10 , Ta- † † estradiol-treated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ 179.7, Critical difference ϭ 86.6, p ϭ .0002); † tamoxifen-treated ovariectomized compared to vehicletreated ovariectomized rats (Mean difference ϭ 99.1, Critical difference ϭ 86.6, p ϭ .02); and raloxifene-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ 101.9, Critical difference ϭ 93.5, p ϭ .03).
Figure 7. L-[
3 H]Glutamate (0.2 mM) specific binding to NMDA receptors in striatum, nucleus accumbens, and olfactory tubercle of intact rats as well as two-weeks ovariectomized rats that received vehicle once daily, s.c., or a twoweek replacement therapy with 17␤-estradiol (80 g/kg), tamoxifen (1 mg/kg), or raloxifene (1 mg/kg). Results are expressed in fmol/mg of tissue Ϯ S.E.M. from six rats. For striatum: F 5,29 ϭ 3.29, p ϭ .01; † estradiol-treated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ 86.1, Critical difference ϭ 63.9, p ϭ .01); tamoxifen-treated ovariectomized compared to vehicletreated ovariectomized rats (Mean difference ϭ 84.7, Critical difference ϭ 67.0, p ϭ .01); and raloxifene-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ 88.6, Critical difference ϭ 63.9, p ϭ .008). For nucleus accumbens: F 5,29 ϭ 2.67, p ϭ .04; † estradioltreated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ 98.8, Critical difference ϭ 79.0, p ϭ .01); tamoxifen-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ 96.1, Critical difference ϭ 82.9, p ϭ .02); and raloxifene-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ 100.5, Critical difference ϭ 79.0, p ϭ .01). For olfactory tubercle: F 5,29 ϭ 0.10, p ϭ .99.
Figure 8. L-[
3 H]Glutamate (0.2 mM) specific binding to NMDA receptors in hippocampal CA1, CA2/3, and dentate gyrus regions of intact rats as well as two-weeks ovariectomized rats that received vehicle once daily, s.c., or a two-week replacement therapy with 17␤-estradiol (80 g/kg), tamoxifen (1 mg/kg), or raloxifene (1 mg/kg). Results are expressed in fmol/mg of tissue Ϯ S.E.M. from six rats. For the hippocampal region, CA1: F 5,28 ϭ 3.46, p ϭ .01, * vehicle-treated ovariectomized compared to intact rats (Mean difference ϭ 156.7, Critical difference ϭ 118.2, p ϭ .01); † † estradiol-treated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ157.1, Critical difference ϭ 112.7, p ϭ .008); † tamoxifen-treated ovariectomized compared to vehicletreated ovariectomized rats (Mean difference ϭ Ϫ119.3, Critical difference ϭ 118.2, p ϭ .04); and raloxifene-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ122.6, Critical difference ϭ 112.7, p ϭ .03). For the hippocampal region, CA2/3: F 5,28 ϭ 0.20, p ϭ .95. For the hippocampal region, dendate gyrus: F 5,28 ϭ 2.79, p ϭ .03, * vehicle-treated ovariectomized compared to intact rats (Mean difference ϭ 107.8, Critical difference ϭ 93.0, p ϭ .02); † estradiol-treated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ112.8, Critical difference ϭ 88.7, p ϭ .01); tamoxifen-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ96.3, Critical difference ϭ 93.0, p ϭ .04); and raloxifene-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ89.3, Critical difference ϭ 88.7, p ϭ .04). (Table 1 ) or in the dentate gyrus (Figure 10 ).
NMDA Receptors mRNA Levels
The mRNA levels encoding the NMDA receptors subunit 1 were not affected by ovariectomy and treatments in the cingulate, frontal, parietal, and piriform cortices (data not shown). The level of NMDA receptor subunit 1 mRNA expression in the striatum was weak but strong enough for quantification and no effect of ovariectomy and treatments were observed in this region (data not shown). Ovariectomy decreased mRNA levels of the NMDA receptor subunits 1 and 2B (25%, p ϭ .003 and 21%, p ϭ .002, respectively) only in the hippocampal CA1 region, whereas the other regions of hippocampus were not significantly affected ( Figure 11 , Table  1 ). Estradiol treatment prevented the ovariectomy induced decrease of mRNA levels of NMDA receptor subunits 1 and 2B in the CA1 (Figure 11) . Similarly, tamoxifen and raloxifene treatments prevented, in the CA1, the ovariectomy induced decrease of mRNA expression of the NMDA receptor subunit 1, that is respectively 20% (p ϭ .05) and 22%(p ϭ .03) higher than ovariectomized rats, whereas they had no significant effect on the mRNA levels of subunit 2B (10%, p ϭ .20 and 15%, p ϭ .06, respectively). Ovariectomy and treatments were without effect on mRNA levels of the † tamoxifen-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ192.9, Critical difference ϭ 188.3, p ϭ .04); and raloxifene-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ172.7, Critical difference ϭ 171.8, p ϭ .04); CA1 Stratum Radiatum: F 5,32 ϭ 2.56, p ϭ .04, ** ovariectomized compared to intact rats (Mean difference ϭ 314.1, Critical difference ϭ 245.3 , p ϭ .01); † estradiol-treated ovariectomized rats compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ273.3, Critical difference ϭ 216.8, p ϭ .01); tamoxifen-treated ovariectomized compared to vehicle-treated ovariectomized rats (Mean difference ϭ Ϫ243.9, Critical difference ϭ 245.3, p ϭ .05); and raloxifene-treated ovariectomized compared to vehicletreated ovariectomized rats (Mean difference ϭ Ϫ245.9, Critical difference ϭ 233.1, p ϭ .03); Dendate gyrus : F 5,34 ϭ 0.26, p ϭ .93.
NMDA receptor subunit 2A in the hippocampal regions assayed ( Figure 11 , Table 1 ) and also, were without effect on mRNA levels of the NMDA receptor subunits 1 and 2B in the pyramidal cell layer of hippocampal CA2/3 regions (Table 1) . (Cyr et al. 2000a) .
[ 1982) ] of intact rats and two-weeks ovariectomized rats that received vehicle once daily, s.c., or a two-week replacement therapy with 17␤-estradiol (80 g/kg), tamoxifen (1 mg/kg), or raloxifene (1mg/kg). Abbreviations: CA1, CA2, and CA3: fields CA1, CA2, and CA3 of hippocampus; DG: dentate gyrus. (Sills et al. 1991), whereas [ 3 H]Ro 25-6981 has more affinity to the polyamine site (Fischer et al. 1997) . Our results are in agreement with a previous report showing no effect of estradiol on L-[ 3 H]CGP 39653 specific binding in the hippocampal regions of ovariectomized rats (Weiland 1992) . Furthermore, the difference between intact and ovariectomized rats observed in the hippocampus is supported by the recent finding that NMDA receptor changes during the estrous cycle (Lu et al. 2000) . So far, it has been shown that specific L-[ 3 H]CGP 39653 binding is possible only when subunit NMDA receptor 2A is present in the heteromeric receptor (Marti et al. 1993; Lynch et al 1994; Laurie and Seeburg 1994; Mugnaini et al. 1996) .
In a more recent study, L-[ 3 H]CGP 39653 is shown to label two pharmacologically distinct populations of NMDA receptors that have pharmacologically and anatomical properties consistent with NMDA receptor subunits 2A and 2B (Christie et al. 2000) . In contrast, [ 3 H]Ro 25-6981 demonstrates a high affinity for the NMDA receptor containing subunit 2B (Fischer et al. 1997; Mutel et al. 1998 ) and the distribution of its binding sites correlates well with that of NMDA receptor subunit 2B transcripts, but not with subunit 2A (Mutel et al. 1998) . These properties of [ 3 H]Ro 25-6981, in addition to our results suggest that the hormonal modulation of NMDA agonist binding sites may be a reflection of the Figure 11 . In situ hybridization of NMDA receptor subunits 1, 2A, and 2B in hippocampal CA1, and dentate gyrus regions of intact rats as well as two-weeks ovariectomized rats that received vehicle once daily, s.c., or a two-week replacement therapy with 17␤-estradiol (80 g/kg), tamoxifen (1 mg/kg), or raloxifene (1 mg/kg). Results are expressed in relative optical density Ϯ S.E.M. from six rats. For CA1, subunit 1: total number of heteromeric NMDA receptor subunits, with higher implication of subunit 2B.
Other glutamate receptor subtypes than NMDA receptors could be implicated positively or negatively in the hormonal modulation of the L-[ 3 H]glutamate specific binding reported so far. Indeed, previous results have demonstrated that non-NMDA receptors such as AMPA receptors can be similarly influenced by estradiol in cortical (Cyr et al. 2000a) but not in hippocampal regions (Weiland 1992; Cyr et al. 2000) or overexpressed in the hypothalamus (Gu et al. 1999) . Moreover, it has been reported that the kainate receptor, another non-NMDA receptor, is not influenced by estradiol (Weiland 1992) . Very little studies have yet directly assessed the influence of sex steroids on the different subtypes of glutamate receptors. The lack of effect on L-[ 3 H]glutamate specific binding after ovariectomy or estradiol treatment in the hippocampus, striatum, and nucleus accumbens may be due to the combined hormonal effect on various glutamate receptor subtypes. This research area needs further investigation in order to clearly understand the exact mechanism of the effect of sex steroids on brain glutamate receptors.
In the CA1 subregion of the hippocampus, our in situ hybridization experiments showed that subunits 1 and 2B, but not 2A, decreased after ovariectomy and that this decrease was prevented by hormonal treatments. These results suggest the implication of a genomic mechanism of action in this specific region of the hippocampus. It has to be noted that our evaluation of the NMDA receptor subunit 1 mRNA reflects a pool of eight potential isoforms in all regions studied (Sugihara et al. 1992; Hollmann et al. 1993) . Previous results have also suggested the implication of a classical genomic mechanism of action. It was reported in two studies (Brann et al. 1993; Gu et al. 1999 ) that estradiol influences mRNA levels of the NMDA receptor subunit 1, whereas another study showed no effect (Gazzaley et al. 1996) . These discrepancies may be due to differences in age, sex, or hormonal treatment paradigms. For example, the estrogen dosage used is higher (20 g/day/ 14 days) and the period of treatment, longer in our studies, compared to the dosage and time (two days) used in the study of Gazzaley et al. (1996) who reported no effect of estradiol. The genomic mechanism of action may be through the intracellular estrogen receptor which has been found in the hippocampus by several methods (Pfaff and Keiner 1973; Loy et al. 1988; Maggi et al. 1989 ).
More recently, both ␣ and ␤ estrogen receptors have been found by immunohistochemistry and in situ hybridization in the hippocampus, located in greatest concentration in the hilus of the dentate gyrus and the stratum radiatum of the CA1 region Shughrue et al. 1997; Laflamme et al. 1998) . Nevertheless, the presence of an estrogen responsive element in the promoter of the rat NMDA receptor subunit 1 (Bai and Kusiak 1993) and 2B (Suchanek et al. 1995) genes, which are already cloned, has not been reported; the promoter of the NMDA receptor subunits 2A has not been cloned yet. However non-hormone response element containing genes, such as the AP1 response element (Paech et al. 1997) , can also respond to the estrogen receptor ligand (Katzenellenbogen et al. 1996 ). An SP1 motif, which is similar to the AP1 motif, has been found in the NMDA receptor subunit 1 (Bai and Kusiak 1993; Bai and Kusiak 1995) and 2B (Suchanek et al. 1995) promoters. Nevertheless, further investigations with gel shift and DNA footprinting assays are required to clearly answer this potential mechanism of action. Alternatively, the effect of estradiol in the CA1 region of the hippocampus may be through other brain regions, such as the septum and may involve other neurotransmitters, such as acetylcholine (Daniel and Dohanich 2000) . Indeed, Daniel and Dohanich (2000) have recently shown that acetylcholine mediates the estrogen-induced increase in the hippocampal NMDA receptor binding and the associated enhancement in working-memory performance.
The NMDA receptor changes observed at the protein level after ovariectomy and hormonal treatments were not associated with similar changes of mRNA levels for this receptor subunits in dentate gyrus of the hippocampus, cerebral cortex, and striatum. This lack of effect may be explained by the cell biology of the transcript versus the final protein localization of NMDA receptors. Transcripts encoding NMDA receptor subunits are localized in the cell bodies of neurons that express these receptors. Hence, the modulation of NMDA receptor binding that we found in a particular brain region may be through modulation of its corresponding transcript in other brain regions containing estrogen receptors. This could also explain why we found changes of both transcript and receptor binding in the CA1 subregion of the hippocampus, which may reflect the short distance between expression of NMDA receptor subunits mRNA in pyramidal cell layers (cell bodies) and expression of their cognate proteins in the oriens and stratum radiatum layers (dendritic projections) (Bernard and Wheal 1994) .
The present experiment provides original evidence that tamoxifen and raloxifene, which have shown low estrogenic activity in the uterus, as demonstrated in other studies (see Cosman and Lindsay 1999 for review), both mimic the effects of estradiol on brain L-[ effect of raloxifene on cognitive performance was observed (Nickelsen et al 1999) . The penetration of raloxifene in blood-brain protected regions is low and may render the detection of any cognitive effects difficult at the dosage currently used in practice (Wu et al. 1999 ). However, Wu et al. (1999) reported that systemic administrations of raloxifene reversed the ovariectomyinduced reduction in choline acetyltransferase activity in the hippocampus of rats.
A nonsteroidal estrogen antagonist, CI-628, was shown to have an antagonist effect by effectively preventing estrogen induction of spines on CA1 pyramidal neurons (McEwen et al. 1999) . In contrast, CI-628 has an estrogen-like agonist activity on brain monoamine oxidase in corticomedial amygdala (reduction of activity) and on choline acetylase in the preoptic area (increase of activity) (Luine and McEwen 1977) . Moreover, tamoxifen was also shown to block the effect of estradiol on dendritic spines of hippocampal neurons (Murphy and Segal 1996) . The raloxifene analogue LY117018 has an estrogen-like action on neuroendocrine opiatergic pathways when administered alone in ovariectomized rats, whereas it exerts an anti-estrogenic effect in fertile or ovariectomized rats treated with 17␤-estradiol (Genazzani et al 1999) .
The mechanism of action of tamoxifen and raloxifene to modulate NMDA receptors like estradiol as well as their brain regions and tissue specificity factors need further investigation. Our results suggest, however, that the mechanism of action of these two nonsteroidal antiestrogens may be the same than estradiol. However, tamoxifen is an inhibitor of protein kinase C (O'Brian et al. 1986 ) and it has been found recently that the physiological properties of NMDA receptors in neurons, which are Ca 2ϩ -permeable glutamate-gated channels, are modulated by protein kinase C (Zheng et al. 1999) . Hence, tamoxifen may modulate [ 3 H]Lglutamate specific binding and NMDA receptors also via its protein kinase C activity.
We have previously reported that estradiol increases 5-hydroxytryptamine-2A receptor density and expression in rat brain and that raloxifene mimics the effect of estradiol (Cyr et al. 2000b ). Moreover, we reported that tamoxifen, in contrast to estradiol and raloxifene, has no significant modulatory effect on brain serotonin 5-hydroxytryptamine-2A receptors of ovariectomized rats , in most brain regions investigated (Cyr et al. 2000b) .
Excitotoxicity has been proposed to be implicated in neurodegenerative diseases, such as Parkinson disease (Dunnett and Bjorklund 1999) and Ifenprodil, a blocker of NMDA receptors, has been shown to have antiparkinsonian activity in humans (Montastruc et al. 1997 ). 17␤-estradiol was reported to protect against NMDAinduced excitotoxicity by direct inhibition of NMDA receptors (Weaver et al. 1997 ) and recently, a positive association was reported between estrogen use and a lower symptom severity in women with early Parkinson disease no yet taking L-Dopa (Saunders-Pullman et al. 1999) .
Since estradiol, tamoxifen, and raloxifene were shown here to decrease striatal NMDA receptors, these hormones mimic the beneficial effect on Parkinson disease seen with excitatory amino acid antagonists. In addition, considering the well established role of the hippocampus (Zola-Morgan et al. 1986; Alvarez et al. 1995) and NMDA receptors (Morris et al. 1982; Bliss and Collingridge 1993) in learning and memory functions, estradiol, tamoxifen, and raloxifene may enhance memory by maintaining NMDA receptors in specific hippocampal regions. Moreover, in the pathophysiology of schizophrenia, human neurochemical and clinical pharmacological data implicate brain glutamatergic abnormalities in the cortex as well as in the hippocampus (Tamminga 1999) . Hence, estradiol, tamoxifen, and raloxifene, by their modulation of NMDA receptors and in particular, the subunits 1 and 2B of the heteromeric receptor, primarily in the hippocampal CA1 region and the cingulate cortex, may have beneficial effect in neurological disorders such as Alzheimer's disease and schizophrenia.
